Phase I Trial of a PSA based vaccine and ipilimumab in patients (pts) with metastatic castrate resistant prostate cancer (CRPC)

被引：0
|
作者：
Gulley, James L. [1 ]
Arlen, Philip M. [1 ]
Madan, Ravi [1 ]
Lechleider, Robert L. [1 ]
Dahut, William L. [1 ]
Lowy, Israel [2 ]
Schlom, Jeffrey [1 ]
机构：
[1] NCI, Bethesda, MD USA
[2] Medarex, Princeton, NJ USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3381S / 3381S
页数：1
相关论文
共 50 条
  • [41] Survival outcomes for men with castrate-resistant prostate cancer (CRPC) treated with a dendritic-cell based vaccine in a randomized controlled trial
    Gardiner, R. A.
    Mactaggart, P.
    Yaxley, J.
    Nicol, D.
    Mcclintock, S.
    Ellem, K.
    Hart, D.
    Seymour, G. J.
    Lopez, A.
    Schmidt, C.
    BJU INTERNATIONAL, 2014, 113 : 34 - 35
  • [42] Outcomes from a phase I trial of an adenovirus/PSA vaccine for prostate cancer
    Lubaroff, David M.
    Konety, Badrinath R.
    Link, Brian K.
    Ratliff, Timothy L.
    Madsen, Tammy
    Williams, Richard D.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 184 - 184
  • [43] SURVIVAL OUTCOMES FOR MEN WITH CASTRATE-RESISTANT PROSTATE CANCER (CRPC) TREATED WITH A DENDRITIC-CELL BASED VACCINE IN A RANDOMIZED CONTROLLED TRIAL
    Gardiner, R. A.
    Mactaggart, P.
    Yaxley, J.
    Nicol, D.
    McClintock, S.
    Ellem, K. A. O.
    Hart, D.
    Seymour, G. J.
    Lopez, A.
    Schmidt, C.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 33 - 34
  • [44] A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
    William R. Schelman
    Glenn Liu
    George Wilding
    Thomas Morris
    De Phung
    Robert Dreicer
    Investigational New Drugs, 2011, 29 : 118 - 125
  • [45] A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
    Schelman, William R.
    Liu, Glenn
    Wilding, George
    Morris, Thomas
    Phung, De
    Dreicer, Robert
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (01) : 118 - 125
  • [46] Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC)
    Scher, H. I.
    Beer, T. M.
    Higano, C. S.
    Danila, D. C.
    Montgomery, B.
    Shelkey, J.
    Hirmand, M.
    Hung, D.
    Sawyers, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in patients (pts) with castration-resistant prostate cancer (CRPC): Preliminary results
    Slovin, S. F.
    Kargman, M.
    Durso, R.
    Curley, T.
    Israel, R. J.
    Olson, W. C.
    Morris, S.
    Murphy, D.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [48] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Molina, A. M.
    Christos, P. J.
    Whang, Y.
    Nordquist, L.
    Hackett, A. L.
    Beltran, H.
    Faltas, B.
    Nanus, D.
    Giannakakou, P.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] A PHASE II STUDY OF SB939 IN PATIENTS (PTS) WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC)
    Eigl, B. J.
    North, S.
    Winquist, E.
    Powers, J.
    Good, J.
    Sharma, M.
    Squire, J.
    Cox, M.
    Eisenhauer, E. A.
    Chi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 304 - 304
  • [50] The tumor immune microenvironment differs between metastatic castrate resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC).
    Yuen, Kobe Chi Yung
    Ben Tran
    Gibbs, Peter
    Anton, Angelyn
    Mariathasan, Sanjeev
    Sandhu, Shahneen Kaur
    Kadel, Edward Ernest
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345